Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment

doi:10.1007/s13238-017-0394-6

Protein Cell

2018, Vol. 9

Issue (6) : 516-526 https://doi.org/10.1007/s13238-017-0394-6

REVIEW

Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment

Yelei Guo¹, Kaichao Feng², Yao Wang¹, Weidong Han^1,²(

)

¹. Molecular & Immunological Department, Chinese PLA General Hospital, Beijing 100853, China
². Bio-therapeutic Department, Chinese PLA General Hospital, Beijing 100853, China

Download: PDF(614 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.

Keywords cancer stem cells chimeric antigen receptor immunotherapy translational medicine response evaluation criterion

Corresponding Author(s): Weidong Han

Issue Date: 11 June 2018

Cite this article:

Yelei Guo,Kaichao Feng,Yao Wang, et al. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment[J]. Protein Cell, 2018, 9(6): 516-526.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-017-0394-6
https://academic.hep.com.cn/pac/EN/Y2018/V9/I6/516

1	Ades F, Yamaguchi N (2015) WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results? Ecancermedicalscience 9:604 https://doi.org/10.3332/ecancer.2015.604
2	Ahmed N, Brawley VS, Hegde Met al. (2015) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified Tcells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33:1688–1696 https://doi.org/10.1200/JCO.2014.58.0225
3	Alamgeer M, Peacock CD, Matsui Wet al. (2013) Cancer stem cells in lung cancer: Evidence and controversies. Respirology 18:757–764 https://doi.org/10.1111/resp.12094
4	Al-Hajj M, Wicha MS, Benito-Hernandez Aet al. (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988 https://doi.org/10.1073/pnas.0530291100
5	Ang W, Li Z, Chi Zet al. (2017) Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. https://doi.org/10.18632/oncotarget.14592
6	Baba T, Convery PA, Matsumura Net al. (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28:209–218 https://doi.org/10.1038/onc.2008.374
7	Bakalova R, Ohba H, Zhelev Zet al. (2004) Quantum dots as photosensitizers? Nat Biotechnol 22:1360–1361 https://doi.org/10.1038/nbt1104-1360
8	Bidlingmaier S, Zhu X, Liu B (2008) The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl). 86:1025–1032 https://doi.org/10.1007/s00109-008-0357-8
9	Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737 https://doi.org/10.1038/nm0797-730
10	Bruce WR, Van Der Gaag HA (1963) Quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199:79–80 https://doi.org/10.1038/199079a0
11	Budde LE, Berger C, Lin Yet al. (2013) Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE 8:e82742 https://doi.org/10.1371/journal.pone.0082742
12	Chao MP, Tang C, Pachynski RKet al. (2011a) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118:4890–4901 https://doi.org/10.1182/blood-2011-02-338020
13	Chao MP, Alizadeh AA, Tang Cet al. (2011b) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71:1374–1384 https://doi.org/10.1158/0008-5472.CAN-10-2238
14	Chen Y,Song J, Jiang Yet al. (2015) Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. Int J Clin Exp Pathol 8:11287–11295
15	Collins AT, Berry PA, Hyde Cet al. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951 https://doi.org/10.1158/0008-5472.CAN-05-2018
16	Corbeil D, Marzesco AM, Wilsch-Brauninger Met al. (2010) The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro) epithelial cell differentiation. FEBS Lett 584:1659–1664 https://doi.org/10.1016/j.febslet.2010.01.050
17	Dai H, Zhang W, Li Xet al. (2015) Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 4:e1027469 https://doi.org/10.1080/2162402X.2015.1027469
18	Deng Z, Wu Y, Ma Wet al. (2015) Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 16:1 https://doi.org/10.1186/s12865-014-0064-x
19	Dragu DL, Necula LG, Bleotu Cet al. (2015) Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells 26:1185–1201
20	Edris B, Weiskopf K, Volkmer AKet al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109:6656–6661 https://doi.org/10.1073/pnas.1121629109
21	Feldmann G, Dhara S, Fendrich Vet al. (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combinationtherapy in solid cancers. Cancer Res 67:2187–2196 https://doi.org/10.1158/0008-5472.CAN-06-3281
22	Feng K, Guo Y, Dai Het al. (2016) Chimeric antigen receptormodified T cells for the immunotherapy of patients with EGFRexpressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59:468–479 https://doi.org/10.1007/s11427-016-5023-8
23	Feng K, Guo Y, Liu Yet al.(2017) Cocktail treatment with EGFRspecific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol 10:4 https://doi.org/10.1186/s13045-016-0378-7
24	Focosi D, Bestagno M, Burrone Oet al. (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87:107–116 https://doi.org/10.1189/jlb.0809566
25	Frank NY, Schatton T, Frank MH (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 120:41–50 https://doi.org/10.1172/JCI41004
26	Fukuda K, Saikawa Y, Ohashi Met al. (2009) Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 34:1201–1207
27	Garfall AL, Maus MV, Hwang WTet al. (2015) Chimeric antigen receptor Tcells against CD19 for multiple myeloma. N Engl J Med 373:1040–1047 https://doi.org/10.1056/NEJMoa1504542
28	Ginestier C, Hur MH, Charafe-Jauffret Eet al. (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567 https://doi.org/10.1016/j.stem.2007.08.014
29	Gires O, Klein CA, Baeuerle PA (2009) On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 9:143 https://doi.org/10.1038/nrc2499-c1
30	Grada Z, Hegde M, Byrd Tet al. (2013) TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2:e105 https://doi.org/10.1038/mtna.2013.32
31	Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-Tcell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024–10028 https://doi.org/10.1073/pnas.86.24.10024
32	Grupp SA, Kalos M, Barrett Det al. (2013) Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518 https://doi.org/10.1056/NEJMoa1215134
33	Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells: mirage or reality? Nat Med 15:1010–1012 https://doi.org/10.1038/nm0909-1010
34	Hemmati HD, Nakano I, Lazareff JAet al. (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178–15183 https://doi.org/10.1073/pnas.2036535100
35	Hibi K, Sakata M, Kitamura YHet al. (2010) Demethylation of the CD133 gene is frequently detected in early gastric carcinoma. Anticancer Res 30:1201–1203
36	Hodi FS, O’Day SJ, McDermott DFet al. (2010) Improved survivalwith ipilimumab in patientswithmetastaticmelanoma. N Engl J Med 363:711–723 https://doi.org/10.1056/NEJMoa1003466
37	Hong IS, Jang GB, Lee HYet al. (2015) Targeting cancer stem cells by using the nanoparticles. Int J Nanomed 10(Spec Iss):251–260
38	Hoos A, Eggermont AM, Janetzki Set al. (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388–1397 https://doi.org/10.1093/jnci/djq310
39	Hoos A, Wolchok JD, Humphrey RWet al. (2015) CCR 20th anniversary commentary: immune-related response criteria-capturing clinical activity in immuno-oncology. Clin Cancer Res 21:4989–4991 https://doi.org/10.1158/1078-0432.CCR-14-3128
40	Jain A, Jain SK (2008) In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci 35:404–416 https://doi.org/10.1016/j.ejps.2008.08.008
41	Jain A, Jain SK, Ganesh Net al. (2010) Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine 6:179–190 https://doi.org/10.1016/j.nano.2009.03.002
42	Jensen MC, Riddell SR (2015) Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33:9–15 https://doi.org/10.1016/j.coi.2015.01.002
43	Julien S,Merino-Trigo A, Lacroix Let al. (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18(19):5314–5328 https://doi.org/10.1158/1078-0432.CCR-12-0372
44	Kastan MB, Schlaffer E, Russo JEet al. (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75:1947–1950
45	Kershaw MH, Westwood JA, Darcy PK (2013) Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525–541 https://doi.org/10.1038/nrc3565
46	Khaleghi S, Rahbarizadeh F, Ahmadvand Det al. (2012) A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int J Hematol 95:434–444 https://doi.org/10.1007/s12185-012-1037-6
47	Khan N, Mukhtar H (2015) Dietary agents for prevention and treatment of lung cancer. Cancer Lett 359:155–164 https://doi.org/10.1016/j.canlet.2015.01.038
48	Kim D, Wang J, Willingham SBet al. (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26:2538–2545 https://doi.org/10.1038/leu.2012.141
49	Kim MS, Ma JS, Yun Het al. (2015) Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc 137:2832–2835 https://doi.org/10.1021/jacs.5b00106
50	Kochenderfer JN, Dudley ME, Kassim SHet al. (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540–549 https://doi.org/10.1200/JCO.2014.56.2025
51	Lamers CH, Sleijfer S, van Steenbergen Set al. (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21:904–912 https://doi.org/10.1038/mt.2013.17
52	Lapidot T, Sirard C, Vormoor Jet al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645–648 https://doi.org/10.1038/367645a0
53	Lee DW, Gardner R, Porter DLet al. (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195 https://doi.org/10.1182/blood-2014-05-552729
54	Li C, Heidt DG, Dalerba Pet al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030–1037 https://doi.org/10.1158/0008-5472.CAN-06-2030
55	Lingala S, Cui YY, Chen Xet al. (2010) Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 89:27–35 https://doi.org/10.1016/j.yexmp.2010.05.005
56	Liu J, Jiang G (2006) CD44 and hematologic malignancies. Cell Mol Immunol 3:359–365
57	Lu JW, Chang JG, Yeh KTet al. (2011) Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem 113:833–838 https://doi.org/10.1016/j.acthis.2011.01.001
58	Ma S, Chan KW, Hu Let al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542–2556 https://doi.org/10.1053/j.gastro.2007.04.025
59	Ma ZL, Chen YP, Song JLet al. (2015) Knock-down of CD24 inhibits proliferation, invasion and sensitizes breast cancer MCF-7 cells to tamoxifen in vitro. Eur Rev Med Pharmacol Sci 19:2394–2399
60	Majeti R, Chao MP, Alizadeh AAet al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286–299 https://doi.org/10.1016/j.cell.2009.05.045
61	Marchitti SA, Brocker C, Stagos Det al. (2008) Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4:697–720 https://doi.org/10.1517/17425255.4.6.697
62	Maude SL, Frey N, Shaw PAet al. (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507 https://doi.org/10.1056/NEJMoa1407222
63	Mitra M, Kandalam M, Verma RSet al. (2010) Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Mol Vis 16:828–842
64	Morgan RA, Yang JC, Kitano Met al. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843–851 https://doi.org/10.1038/mt.2010.24
65	Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627–5629 https://doi.org/10.1158/0008-5472.CAN-09-0654
66	Naujokat C (2012) Targeting human cancer stem cells with monoclonal antibodies. J Clin Cell Immunol S5:7 https://doi.org/10.4172/2155-9899.S5-007
67	O’Brien CA, Pollett A, Gallinger Set al. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110 https://doi.org/10.1038/nature05372
68	Ogura E, Senzaki H, Yoshizawa Ket al. (1998) Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res 18:3669–3675
69	Osta WA, Chen Y, Mikhitarian Ket al. (2004) EpCAM is overexpressed inbreast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824 https://doi.org/10.1158/0008-5472.CAN-04-0754
70	Pan Q, Li Q, Liu Set al. (2015) Concise review: targeting cancer stem cells using immunologic approaches. Stem Cells 33:2085–2092 https://doi.org/10.1002/stem.2039
71	Porter DL, Levine BL, Kalos Met al. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733 https://doi.org/10.1056/NEJMoa1103849
72	Rege TA, Hagood JS (2006) Thy-1 as a regulator of cell-cell and cellmatrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 20:1045–1054 https://doi.org/10.1096/fj.05-5460rev
73	Reya T, Morrison SJ, Clarke MFet al. (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111 https://doi.org/10.1038/35102167
74	Ricci-Vitiani L, Lombardi DG, Pilozzi Eet al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111–115 https://doi.org/10.1038/nature05384
75	Rosfjord E, Lucas J, Li Get al. (2014) Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem Pharmacol 91(2):135–143 https://doi.org/10.1016/j.bcp.2014.06.008
76	Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388–398 https://doi.org/10.1158/2159-8290.CD-12-0548
77	Salomon J, Goulet O, Canioni Det al. (2014) Genetic characterization of congenital tufting enteropathy: epcam associated phenotype and involvement of SPINT2 in the syndromic form. Hum Genet 133:299–310 https://doi.org/10.1007/s00439-013-1380-6
78	Savona MR, Malcovati L, Komrokji Ret al. (2015) An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (mds/mpn) in adults. Blood 125:1857–1865 https://doi.org/10.1182/blood-2014-10-607341
79	Schmidt M, Scheulen ME, Dittrich Cet al. (2010) An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 21:275–282 https://doi.org/10.1093/annonc/mdp314
80	Shigdar S, Lin J, Yu Y, Pastuovic Met al. (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991–998 https://doi.org/10.1111/j.1349-7006.2011.01897.x
81	Shmelkov SV, St Clair R, Lyden Det al. (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37:715–719 https://doi.org/10.1016/j.biocel.2004.08.010
82	Skubitz AP, Taras EP, Boylan KLet al. (2013) Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 130:579–587 https://doi.org/10.1016/j.ygyno.2013.05.027
83	Smith LM, Nesterova A, Ryan MCet al. (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100–109 https://doi.org/10.1038/sj.bjc.6604437
84	Song G, Liao X, Zhou Let al. (2004) HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk Res 28:1089–1096 https://doi.org/10.1016/j.leukres.2004.02.005
85	Song Y, Zhu Z, An Yet al. (2013) Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem 85:4141–4149 https://doi.org/10.1021/ac400366b
86	Stewart BW, Wild C, International Agency for Research on Cancer and World Health Organization (2014) World cancer report 2014. International Agency for Research on Cancer WHO Press, Lyon, France/Geneva, Switzerland
87	Strioga M, Pasukoniene V, Characiejus D (2011) CD8+ CD28- and CD8+CD57+ T cells and their role in health and disease. Immunology 134:17–32 https://doi.org/10.1111/j.1365-2567.2011.03470.x
88	Su YJ, Lin WH, Chang YWet al. (2015) Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties. Oncotarget 6:38029–38045 https://doi.org/10.18632/oncotarget.5703
89	Sukowati CH, Anfuso B, Torre Get al. (2013) The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS ONE 8:e76830 https://doi.org/10.1371/journal.pone.0076830
90	Swaminathan SK, Roger E, Toti Uet al. (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171:280–287 https://doi.org/10.1016/j.jconrel.2013.07.014
91	Tang KH, Dai YD, Tong Met al. (2013) A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 73:2322–2332 https://doi.org/10.1158/0008-5472.CAN-12-2991
92	Till BG, Jensen MC, Wang Jet al. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940–3950 https://doi.org/10.1182/blood-2011-10-387969
93	Van der Gun BT, Melchers LJ, Ruiters MHet al. (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31:1913–1921 https://doi.org/10.1093/carcin/bgq187
94	Visus C, Wang Y, Lozano-Leon Aet al. (2011) Targeting ALDH bright human carcinoma-initiating cells with ALDH1A1-Specific CD8+ T cells. Clin Cancer Res 17:6174–6184 https://doi.org/10.1158/1078-0432.CCR-11-1111
95	Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755–768 https://doi.org/10.1038/nrc2499
96	Wang L, Su W, Liu Zet al. (2012) CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 33:5107–5114 https://doi.org/10.1016/j.biomaterials.2012.03.067
97	Wang Y, Zhang WY, Han QWet al. (2014) Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptormodified T cells. Clin Immunol 155:160–175 https://doi.org/10.1016/j.clim.2014.10.002
98	Wang QS, Wang Y, Lv HYet al. (2015a) Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23:184–191 https://doi.org/10.1038/mt.2014.164
99	Wang X, Liu Y, Zhou Ket al. (2015b) Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line. Int J Clin Exp Pathol 8:5105–5112
100	Willingham SB, Volkmer JP, Gentles AJet al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662–6667 https://doi.org/10.1073/pnas.1121623109
101	Wolchok JD, Hoos A, O’Day Set al. (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin Cancer Res 15:7412–7420 https://doi.org/10.1158/1078-0432.CCR-09-1624
102	Woo SR, Oh YT, An JYet al. (2015) Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness. Anat Cell Biol 48:44–53 https://doi.org/10.5115/acb.2015.48.1.44
103	Wu RC, Liu S, Chacon JAet al. (2012) Detection and characterization of a novel subset of CD8(+)CD57(+) T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res 18:2465–2477 https://doi.org/10.1158/1078-0432.CCR-11-2034
104	Wu CY, Roybal KT, Puchner EMet al. (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350:4077 https://doi.org/10.1126/science.aab4077
105	Yamashita T, Wang XW (2013) Cancer stem cells in the development of liver cancer. J Clin Invest 123:1911–1918 https://doi.org/10.1172/JCI66024
106	Yee C, Thompson JA, Byrd Det al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168–16173 https://doi.org/10.1073/pnas.242600099
107	Yi JM, Tsai HC, Glöckner SCet al. (2008) Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68:8094–8103 https://doi.org/10.1158/0008-5472.CAN-07-6208
108	Yin AH, Miraglia S, Zanjani EDet al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002–5012
109	Zhang Q, Shi S, Yen Yet al. (2010) A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289:151–160 https://doi.org/10.1016/j.canlet.2009.08.010
110	Zhang C, Zhou C, Wu XJet al. (2014a) Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells. Carcinogenesis 35:2771–2777 https://doi.org/10.1093/carcin/bgu192
111	Zhang YH, Wang ZY, Hao FYet al.l (2014b) Cluster of differentiation 24 monoclonal antibody induces apoptosis in the osteosarcoma cells. Eur Rev Med Pharmacol Sci 18:2038–2041
112	Zhao L, Yang Y, Zhou Pet al. (2015) Targeting CD133 high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody. J Immunother 38:217–228 https://doi.org/10.1097/CJI.0000000000000086
113	Zhu J, Thakolwiboon S, Liu Xet al. (2014) Overexpression of CD90 (Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment. PLoS ONE 9:e115507 https://doi.org/10.1371/journal.pone.0115507
114	Zhu X, Prasad S, Gaedicke Set al.l (2015) Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget 6:171–184 https://doi.org/10.18632/oncotarget.2767

[1]	Yanjing Song, Chuan Tong, Yao Wang, Yunhe Gao, Hanren Dai, Yelei Guo, Xudong Zhao, Yi Wang, Zizheng Wang, Weidong Han, Lin Chen. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo[J]. Protein Cell, 2018, 9(10): 867-878.
[2]	William R. Strohl. Current progress in innovative engineered antibodies[J]. Protein Cell, 2018, 9(1): 86-120.
[3]	Jiangtao Ren, Yangbing Zhao. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9[J]. Protein Cell, 2017, 8(9): 634-643.
[4]	Hua Li, Yangbing Zhao. Increasing the safety and efficacy of chimeric antigen receptor T cell therapy[J]. Protein Cell, 2017, 8(8): 573-589.
[5]	Dongfang Liu, Shuo Tian, Kai Zhang, Wei Xiong, Ndongala Michel Lubaki, Zhiying Chen, Weidong Han. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV[J]. Protein Cell, 2017, 8(12): 861-877.
[6]	Zhenguang Wang, Yelei Guo, Weidong Han. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment[J]. Protein Cell, 2017, 8(12): 896-925.
[7]	Zhiju Zhao,Shu Li,Erwei Song,Suling Liu. The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells[J]. Protein Cell, 2016, 7(2): 89-99.
[8]	Nicholas Borcherding,David Kusner,Guang-Hui Liu,Weizhou Zhang. ROR1, an embryonic protein with an emerging role in cancer biology[J]. Protein Cell, 2014, 5(7): 496-502.
[9]	Juan Ma,Huamin Han,Li Ma,Changzhen Liu,Xin Xue,Pan Ma,Xiaomei Li,Hua Tao. The immunostimulatory effects of retinoblastoma cell supernatant on dendritic cells[J]. Protein Cell, 2014, 5(4): 307-316.
[10]	Shuanglin Deng,Shan Zhu,Yuan Qiao,Yong-Jun Liu,Wei Chen,Gang Zhao,Jingtao Chen. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma[J]. Protein Cell, 2014, 5(12): 899-911.

Viewed

Full text

Abstract

Cited

Shared

Discussed